Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by CAMP4 Therapeutics

CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
CAMP4 Appoints Multiple Industry Veterans to its Board of Directors
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
CAMP4 to Participate in Upcoming Investor Conferences
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP KRRO
CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
CAMP4 Reports Third Quarter 2024 Financial Results
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
CAMP4 Announces Pricing of Initial Public Offering
From CAMP4 Therapeutics
Via GlobeNewswire
Tickers CAMP
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
From CAMP4 Therapeutics
Via GlobeNewswire
Research from the Lab of CAMP4 Co-Founder Richard Young Shows That RNA Binding to Transcription Factors Fine-Tunes Gene Expression
From CAMP4 Therapeutics
Via Business Wire
CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic
From CAMP4 Therapeutics
Via Business Wire
CAMP4 Therapeutics Promotes Kelly Gold to Chief Financial Officer
From CAMP4 Therapeutics
Via Business Wire
CAMP4 Therapeutics Appoints Veteran Drug Developer Ann Barbier, M.D., Ph.D. as Chief Medical Officer
From CAMP4 Therapeutics
Via Business Wire
CAMP4 Presents In Vivo Data Supporting Novel Therapeutic Strategy for Dravet Syndrome at American Epilepsy Society Annual Meeting
From CAMP4 Therapeutics
Via Business Wire
CAMP4 Presents First Preclinical Data Demonstrating the Therapeutic Potential of its RNA Actuating Platform at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
From CAMP4 Therapeutics
Via Business Wire
CAMP4 Therapeutics Expands Leadership and Board of Directors
From CAMP4 Therapeutics
Via Business Wire
CAMP4 Raises $45 Million to Usher in a New Era of Programmable Therapeutics to Upregulate Genes
From CAMP4 Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.